Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome
ConditionAnti Phospholipid Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNew Valley University
About this trial
AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged ≥18 years
Patients with anemia consistant with hemolysis.
Patient diagnosed with antiphospholipid syndrome.
Informed consent obtained
Disqualifiers
Age less than 18 years.
Other causes of anemia than autoimmune hemolysis.
Trial design
Design model
Single group
Treatments tested in this trial
Hemoglobin
Diagnostic testBlood sample
Coombs test
Diagnostic testBlood sample
Treatment groups
230 Participants
are divided into 2 treatment groupsGroup A: Antiphospholipid syndrome patients with AIHAActive comparator 2 interventions
Group B: Antiphospholipid syndrome patients without AIHAActive comparator 2 interventions
Trial outcomes
Primary outcomes
1
Number of thrombotic events in APS patients with AIHA
Time frame
baselineSecondary outcomes
1
Number of thrombotic events in APS patients aithout AIHA
Time frame
baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov